HVO: Record orderbook and CRS Berlin acquisition set the stage for strong growth in 2027
Revenue for H1 2026 declined to £16.3 million with an adjusted EBITDA loss of £4.5 million, but a record orderbook and strong proposal volumes position the group for significant growth in 2027. The acquisition of CRS Berlin expands the clinical platform and is expected to be earnings accretive.Orig…
Revenue for H1 2026 declined to £16.3 million with an adjusted EBITDA loss of £4.5 million, but a record orderbook and strong proposal volumes position the group for significant growth in 2027. The acquisition of CRS Berlin expands the clinical platform and is expected to be earnings accretive.Orig…